Deutsche Bank Raises PT on Teva Pharma to $48

Symbols: TEVA
Share

Deutsche Bank has raised the price target on Teva Pharmaceuticals (NASDAQ: TEVA) from $46 to $48 and maintains its Buy rating.


 
 
< Previous
Goldman Sachs Lowers PT On CarMax to $29
Next >
Piper Jaffray Assumes Coverage on Elster Group at Overweight
Share
Printer-friendly version
Send to friend
We're Loving

Benzinga's Premium Memberships

Benzinga's News Delivered Free

Brain Trust